Search

Purpose: To compare subfoveal choroidal thickness (SFCT) between eyes with choroidal melanoma and choroidal nevi., Methods: Retrospective study of 126 consecutive patients in a tertiary ocular oncology center. Eyes with tumors located less than two disc-diameters from the fovea were excluded. In eyes with naevi, factors of potential transformation into melanoma were recorded (orange pigment, subretinal fluid, thickness >2 mm, diameter >5 mm, ultrasound hollowness). SFCT was assessed by 3 independent observers on horizontal spectral-domain OCT scans., Results: Sixty-seven eyes with choroidal melanoma and 59 eyes with choroidal nevi were included. The melanoma and nevi groups did not differ in gender (P=0.14) nor age (P=0.34). There was a very good agreement between the three independent observers for SFCT measurements (intraclass correlation coefficient=0.89). Mean SFCT was higher in melanomas (294.3±89.9 µm) than naevi (260.3±76.7 µm) (P=0.013), and the difference remained significant between melanomas and 28 naevi with ≥2 growth risk factors (256.3±77.0 µm) (P=0.027). In a multivariate model, the significant contributors to SFCT were presence of melanoma (P=0.004), younger age (P<0.0001) and shorter lesion distance to the fovea (P=0.016)., Conclusion: SFCT may reflect the interplay between melanocytic tumors and their choroidal microenvironment. Its clinical utility should be explored in future studies.

Purpose of Review: The aim of this study was to highlight the diagnostic and management challenges of primary vitreoretinal lymphoma (PVRL) through a review of the literature and a European survey on real-life practices for PVRL., Recent Findings: The care of PVRL patients is heterogeneous between specialists and countries. Upfront systemic treatment based on high-dose methotrexate chemotherapy, with or without local treatment, might reduce or delay the risk of brain relapse.Ibrutinib, lenalidomide with or without rituximab, and temozolomide are effective for patients with relapsed/refractory PVRL and should be tested as first-line treatments., Summary: The prognosis of PVRL remains dismal. No firm conclusion regarding optimal treatment can yet be drawn. The risk of brain relapse remains high. Diagnostic procedures and assessment of therapeutic responses need to be homogenized. Collaboration between specialists involved in PVRL and multicentric prospective therapeutic studies are strongly needed. The recommendations of the French group for primary oculocerebral lymphoma (LOC network) are provided, as a basis for further European collaborative work., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)